Patient characteristics at baseline.
| Characteristics | All Patients, n = 28 | MTX Group, n = 10 | TNF-α Group, n = 18 |
|---|---|---|---|
| Age, yrs | 51.7 (15.2) | 58.6 (15.8) | 47.8 (13.8) |
| Sex, female:male | 23:5 | 7:3 | 16:2 |
| Race, n | |||
| White | 12 | 6 | 6 |
| Hispanic or Latino | 7 | 2 | 5 |
| Pacific Islander | 1 | 0 | 1 |
| African American | 2 | 0 | 2 |
| Declined to report | 6 | 2 | 4 |
| Body mass index, kg/m2 | 28.6 (8.1) | 24.5 (5.5) | 30.9 (8.5) |
| RA onset, yrs | 5.6 (5.4) | 7.1 (5.2) | 4.7 (5.5) |
| MTX dose, mg | 14.8 (7.3) | 13.0 (7.9) | 16.2 (6.4) |
| Other DMARD, n | 1 (SSZ) | 0 | 1 (SSZ) |
| Prednisone dose, mg | 4.5 (3.8) | 1.3 (4.1) | 6.3 (3.3) |
| mTSS score | 30.7 (32.0) | 26.5 (15.6) | 33.1 (33.9) |
Data presented as mean (SD) unless otherwise indicated. MTX: methotrexate; TNF-α: tumor necrosis factor–α; DMARD: disease-modifying antirheumatic drugs; mTSS: modified total Sharp score; SSZ: sulfasalazine; RA: rheumatoid arthritis.